# Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change

> **NCT06053541** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 3015000 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06053541
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 3015000 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06053541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06053541, "Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06053541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*